SAN DIEGO — NOV03, a novel, single chemical entity molecule, showed improvement in evaporative dry eye symptoms in the phase 2 SEECASE trial, Joseph Tauber, MD, said at the American Society of Cataract and Refractive Surgery meeting.
The randomized, double-masked, comparison trial included two dosing schedules of NOV03 (perfluorohexyloctane, Novaliq), twice daily and four times daily, and one dosing schedule of saline.
“Because NOV03 does not have a vehicle per se – being a single chemical entity – saline was selected by the FDA as the comparator eye drop,” Tauber
Uncategorized